About Us

Verseau Therapeutics
Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. With our proprietary all-human translational system we identify novel targets and develop therapies that shift macrophages between immune activators and silencers in disease. Our data suggest that we can at least double the patient population benefitting from immunotherapy. Our initial focus is building a pipeline of first-in-class therapies that modulate macrophages to trigger a coordinated immune attack on cancer.

Read our factsheet to learn more about our science.

Team

Executive Team

Christine Bunt, Ph.D.

Chief Executive Officer and Chairman of the Board

Christine Bunt has served as Chief Executive Officer and Chairman of the Board at Verseau since March 2017. Christine is a serial entrepreneur, investor, founder & CEO of life sciences companies. She is a Partner with 20/20 HealthCare Partners, a private global investment group, managing the biotechnology sector. Prior to joining Verseau, Christine was the CEO and founder of INTICA Biomedical (Personalized Medicine/Cancer) and TARIS Biomedical. TARIS was co-founded with Prof. Michael Cima and Prof. Robert Langer from MIT and acquired by Allergan in 2014 for $588 MM. Previously, Christine was with Merck & Co. in Whitehouse Station, NJ, where she assumed various leadership positions in worldwide commercialization for inflammation, neuroscience and cardiovascular products. Prior to Merck & Co., Christine assumed various R&D, business management and commercialization functions at Hoffmann- La Roche in Basel, Switzerland. Christine holds degrees in medical technology and immunochemistry (biochemistry) from the Institute for Hygiene and Infectious Diseases / Medical School of the University of Saarbrücken, Germany.

Christine mentors entrepreneurs and new technology start-ups at the MIT Deshpande Center. She serves on the boards of the BIDMC (Beth Israel Deaconess Medical Center) Cancer Center and the HMS (Harvard Medical School) Institute for RNA Medicine.

Robert Crane, MBA

Chief Financial Officer

Robert Crane has served as Chief Financial Officer at Verseau since June 2017. Robert has 30 years of experience in the life sciences industry including therapeutics, medical devices and diagnostics. He has served as Chief Financial Officer at a variety of companies including Sirtris Pharmaceuticals, Inc., which was acquired by GlaxoSmithKline Plc; I-STAT Corporation, Inc., which was acquired by Abbott Laboratories; InKine Pharmaceutical Company, Inc., which was acquired by Salix, Inc.; Seragen, Inc., which was acquired by Ligand Pharmaceuticals, Inc.; and GI Dynamics where he was responsible for raising over $225 million. Robert has held senior roles at public and private firms in the U.S., Europe and Asia, and served as Chief Financial Officer at four U.S. public companies. Robert has been responsible for several IPOs and numerous financings with proceeds over $700 million as well as many partnerships and collaborations. Robert was previously a partner in the venture capital firm, Montgomery Ventures and Chairman of the American Bicycle Group. Robert holds a B.S. in mechanical engineering from the Massachusetts Institute of Technology (MIT) and an MBA from Stanford University.

Igor Feldman, Ph.D.

Co-Founder and Head of Computational Biology

Igor Feldman is a Co-Founder and has served as the Head of Computational Biology at Verseau since January 2017. Igor has held positions at Merck & Co., Rosetta Informatics, Jounce Therapeutics and Epizyme. He has been involved in discovery and clinical development using large omics datasets of human tumors, drug response biomarker discovery, novel target discovery in immuno-oncology and epigenetics and establishing computational infrastructure from the ground up for early discovery and development support in several biotech startup companies. He is an inventor on eight U.S. patents. Igor holds a B.S. in biology and a Ph.D. in systems biology from Columbia University.

Tatiana Novobrantseva, Ph.D.

Co-Founder and Head of Research and Development

Tatiana Novobrantseva is a Co-Founder and has served as Head of Research and Development at Verseau since January 2017. Prior to co-founding Verseau, she consulted for multiple companies on immunological aspects of drug development across different stages and therapeutic modalities in a variety of autoimmune, cancer and rare disease indications. At her prior position as Director of Tumor Immunology at Jounce Therapeutics, Tatiana defined research plans for several programs at the company’s inception, as well as led a portfolio of programs on (re)activating the immune system against cancer. Previously, Tatiana served as Associate Director at Alnylam Pharmaceuticals and Scientist II at Biogen. Tatiana’s scientific accomplishments include discovering the critical role for B cells in liver fibrosis, developing mechanistic insights for multiple therapeutic programs, pushing the envelope on siRNA delivery and championing a dendritic cell cancer vaccine clinical program. Tatiana is an inventor on more than 22 patents and an author on more than 37 peer-reviewed manuscripts. Tatiana completed her Ph.D. with Dr. Klaus Rajewsky at the University of Cologne in Germany, focusing on B cell development and function. She holds a diploma of engineer-physicist and an M.S. in molecular biology from Moscow Institute of Physics and Technology.

 

Board of Directors

Christine Bunt, Ph.D.

Chief Executive Officer and Chairman, Verseau

Christine Bunt has served as Chief Executive Officer and Chairman of the Board at Verseau since March 2017. Christine is a serial entrepreneur, investor, founder & CEO of life sciences companies. She is a Partner with 20/20 HealthCare Partners, a private global investment group, managing the biotechnology sector. Prior to joining Verseau, Christine was the CEO and founder of INTICA Biomedical (Personalized Medicine/Cancer) and TARIS Biomedical. TARIS was co-founded with Prof. Michael Cima and Prof. Robert Langer from MIT and acquired by Allergan in 2014 for $588 MM. Previously, Christine was with Merck & Co. in Whitehouse Station, NJ, where she assumed various leadership positions in worldwide commercialization for inflammation, neuroscience and cardiovascular products. Prior to Merck & Co., Christine assumed various R&D, business management and commercialization functions at Hoffmann- La Roche in Basel, Switzerland. Christine holds degrees in medical technology and immunochemistry (biochemistry) from the Institute for Hygiene and Infectious Diseases / Medical School of the University of Saarbrücken, Germany.

Christine mentors entrepreneurs and new technology start-ups at the MIT Deshpande Center. She serves on the boards of the BIDMC (Beth Israel Deaconess Medical Center) Cancer Center and the HMS (Harvard Medical School) Institute for RNA Medicine.

Daniel Anderson, Ph.D.

Co-Founder, Verseau
Professor, Applied Biology, Koch Institute, MIT

Dr. Daniel Anderson is a Co-Founder of Verseau and has served as a board member since March 2017. He is a leading researcher in the field of nanotherapeutics and biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. The research done in his laboratory is focused on developing new materials for medicine. He has pioneered the development of smart biomaterials, and his work has led to advances in a range of areas, including medical devices, cell therapy, drug delivery, gene therapy and material science. Dr. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. Dr. Anderson’s work has resulted in the publication of over 400 papers, patents and patent applications. These advances have led to products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology, and consumer product spaces including CRISPR Tx (Nasdaq:CRSP), Living Proof, Sigilon, Verseau Tx and Olivo Labs.

Jong Chang, MBA

Founder & Chairman, InHarv Partners

Jong Chang has served as a board member of Verseau since March 2017. He is the Founder and Chairman of InHarv Partners Ltd., a hybrid of VC and private equity based in Seoul, Korea whose strategic stance is to raise capital in South Korea for investment in cutting edge tech startups overseas, linking those startups to the Korean industries. He was previously Lead Partner of Booz Allen Hamilton, a global general management consultancy in the U.S., and a Senior Vice President and founding member of KBRI (now Moody’s Korea Inc.), the first credit rating agency in Seoul. As a previous corporate finance manager of the Korea Merchant Bank Corporation, a joint venture with Lazard Brothers U.K., Jong specialized in international mega-project financing and cross border M&As. He served as Junior Economist of the Korea Development Bank and as a member of The National Economic Counsel to Mr. President of South Korea. Jong also held positions as an independent board member of LG Chemical Co. of the LG Group based in Seoul and as an independent board member of Saint-Gabain Korea, a leading flat glass maker. Presently, Jong is the Chairman of the Board of ToolGen, Inc. a world leading DNA editing company based in Seoul Korea. Jong graduated cum laude with a B.A. from So-Gang University in South Korea and holds his MBA from the Wharton School of Business at the University of Pennsylvania.

Wen Chen, MBA

Senior Vice President, Tigermed Co. Ltd.

Wen Chen has served as a board member of Verseau since March 2017. He is the Senior Vice President of Tigermed Co. Ltd., a publicly traded company located in China. Tigermed is a leading contract research organization in China, Asia Pacific dedicated to providing professional clinical development services to the pharmaceutical and medical device industries. Wen represents Yonghua Capital, a leading private equity and venture capital investment firm from China that has invested in Verseau Therapeutics. Wen received a bachelor’s degree in biochemistry from Purdue University, West Lafayette, IN and a master’s degree in immunology and oncology and business administration from Washington University in St. Louis and Durham University, respectively. He then worked at Amgen research before returning to work in the China biotechnology industry since 2000.

Robert Langer, Ph.D.

Co-Founder, Verseau
David H. Koch Professor, Koch Institute, MIT

Dr. Robert Langer is a Co-Founder of Verseau and has served as a board member since March 2017. He is an Institute Professor at the Massachusetts Institute of Technology (MIT). He has written over 1,200 articles, which have been cited over 90,000 times; his h-index of 148 is the highest of any engineer in history. He has 815 issued and pending patents worldwide. His patents have been licensed or sublicensed to over 250 companies. He served as Chairman of the FDA’s Science Board (its highest advisory board) from 1999-2002. His over 220 awards include both the United States National Medal of Science and the United States National Medal of Technology and Innovation, as well as the Charles Stark Draper Prize (considered the engineering Nobel Prize), Albany Medical Center Prize, the Wolf Prize for Chemistry, the Millennium Technology Prize, the Priestley Medal (highest award of the American Chemical Society), the Gairdner Prize and the Lemelson-MIT prize, for being “one of history’s most prolific inventors in medicine.” He holds 20 honorary doctorates, including honorary degrees from Harvard University and Yale University. Dr. Langer is one of the few individuals ever to have been elected to the Institute of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.

 

Scientific Advisory Board

Lisa Coussens, Ph.D.

Read more

Siamon Gordon, Ph.D.

Read more

Alberto Mantovani, M.D.

Read more

Matthias Nahrendorf, M.D., Ph.D.


Read more

George W. Sledge Jr., M.D.

Read more

Filip Swirski, Ph.D.


Read more

 

Advisors

Antoine Awad
Senior Advisor, Verseau
Head of Technical Operations, Synlogic Therapeutics

George Golumbeski, Ph.D.
Senior Advisor, Verseau
President, Head of Corporate Development and Strategy, Grail

Investors

 

Contact

Contact us at info@verseautx.com